Based on the significant progress made over the last few decades with RNA therapeutics, RNA editing is widely considered the next generation of promising medicines in this field. RNA therapies have made significant progress over the last few years, with an increasing...
Wave Life Sciences Ltd., an RNA medicines company, has announced its first clinical trial application for WVE-006, a revolutionary RNA editing therapeutic candidate aimed at treating alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder causing lung and...
Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients...
